TTK Healthcare Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 23, 2025, 10:09 am

Quick Insight

TTK Healthcare Ltd, in the pharmaceutical industry, displays a P/E ratio of 23.8, indicating investors are willing to pay 23.8 times earnings for the stock. With a ROE of 6.89% and ROCE of 9.26%, the company's profitability and capital efficiency seem moderate. The OPM at 6% reflects the company's operational efficiency, while a P/BV ratio of 1.59x suggests the stock may be undervalued in comparison to its book value. TTK Healthcare's strong ICR of 31.91x indicates its ability to meet interest obligations comfortably. However, the company's low net profit of 82 Cr. raises concerns about its bottom line performance, despite a healthy market cap of 1,603 Cr. Overall, while TTK Healthcare shows promise with its operational metrics and investor base, improving profitability could be a key area for the company's future growth and valuation.

Competitors of TTK Healthcare Ltd

All Competitor Stocks of TTK Healthcare Ltd

Quarterly Result

Last Updated: August 20, 2025, 2:00 am

Below is a detailed analysis of the quarterly data for TTK Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 226.00 Cr.. The value appears strong and on an upward trend. It has increased from 190.00 Cr. (Mar 2025) to 226.00 Cr., marking an increase of 36.00 Cr..
• For Expenses, as of Jun 2025, the value is 224.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 178.00 Cr. (Mar 2025) to 224.00 Cr., marking an increase of 46.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 9.00 Cr..
• For OPM %, as of Jun 2025, the value is 1.00%. The value appears to be declining and may need further review. It has decreased from 6.00% (Mar 2025) to 1.00%, marking a decrease of 5.00%.
• For Other Income, as of Jun 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 4.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
• For Net Profit, as of Jun 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 3.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 9.20. The value appears to be declining and may need further review. It has decreased from 11.43 (Mar 2025) to 9.20, marking a decrease of 2.23.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:38 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:10 pm

Below is a detailed analysis of the balance sheet data for TTK Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,051.00 Cr.. The value appears strong and on an upward trend. It has increased from 987.00 Cr. (Mar 2024) to 1,051.00 Cr., marking an increase of 64.00 Cr..
• For Borrowings, as of Mar 2025, the value is 24.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 23.00 Cr. (Mar 2024) to 24.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 192.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 183.00 Cr. (Mar 2024) to 192.00 Cr., marking an increase of 9.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,281.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,206.00 Cr. (Mar 2024) to 1,281.00 Cr., marking an increase of 75.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 81.00 Cr.. The value appears strong and on an upward trend. It has increased from 75.00 Cr. (Mar 2024) to 81.00 Cr., marking an increase of 6.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2024) to 11.00 Cr., marking a decrease of 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,189.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,118.00 Cr. (Mar 2024) to 1,189.00 Cr., marking an increase of 71.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,206.00 Cr. (Mar 2024) to 1,281.00 Cr., marking an increase of 75.00 Cr..

Notably, the Reserves (1,051.00 Cr.) exceed the Borrowings (24.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for TTK Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
• For Diluted EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
• For Cash EPS (Rs.), as of Mar 25, the value is 63.69. This value is within the healthy range. It has increased from 53.71 (Mar 24) to 63.69, marking an increase of 9.98.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 753.73. It has increased from 705.23 (Mar 24) to 753.73, marking an increase of 48.50.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 753.73. It has increased from 708.35 (Mar 24) to 753.73, marking an increase of 45.38.
• For Dividend / Share (Rs.), as of Mar 25, the value is 10.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 567.22. It has increased from 532.75 (Mar 24) to 567.22, marking an increase of 34.47.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 75.07. This value is within the healthy range. It has increased from 70.72 (Mar 24) to 75.07, marking an increase of 4.35.
• For PBIT / Share (Rs.), as of Mar 25, the value is 69.18. This value is within the healthy range. It has increased from 61.48 (Mar 24) to 69.18, marking an increase of 7.70.
• For PBT / Share (Rs.), as of Mar 25, the value is 76.67. This value is within the healthy range. It has increased from 59.53 (Mar 24) to 76.67, marking an increase of 17.14.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
• For PBDIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 13.27 (Mar 24) to 13.23, marking a decrease of 0.04.
• For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.54 (Mar 24) to 12.19, marking an increase of 0.65.
• For PBT Margin (%), as of Mar 25, the value is 13.51. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.51, marking an increase of 2.34.
• For Net Profit Margin (%), as of Mar 25, the value is 10.18. This value exceeds the healthy maximum of 10. It has increased from 8.34 (Mar 24) to 10.18, marking an increase of 1.84.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.66. This value is below the healthy minimum of 15. It has increased from 6.30 (Mar 24) to 7.66, marking an increase of 1.36.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 10. It has increased from 8.64 (Mar 24) to 9.13, marking an increase of 0.49.
• For Return On Assets (%), as of Mar 25, the value is 6.37. This value is within the healthy range. It has increased from 5.23 (Mar 24) to 6.37, marking an increase of 1.14.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 5.23. This value exceeds the healthy maximum of 3. It has decreased from 5.50 (Mar 24) to 5.23, marking a decrease of 0.27.
• For Quick Ratio (X), as of Mar 25, the value is 4.72. This value exceeds the healthy maximum of 2. It has decreased from 5.01 (Mar 24) to 4.72, marking a decrease of 0.29.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 4. It has decreased from 1.91 (Mar 24) to 1.90, marking a decrease of 0.01.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 22.48 (Mar 24) to 0.00, marking a decrease of 22.48.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 18.61 (Mar 24) to 0.00, marking a decrease of 18.61.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 77.52 (Mar 24) to 0.00, marking a decrease of 77.52.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 81.39 (Mar 24) to 0.00, marking a decrease of 81.39.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 31.91. This value is within the healthy range. It has decreased from 36.27 (Mar 24) to 31.91, marking a decrease of 4.36.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.38. This value is within the healthy range. It has decreased from 23.81 (Mar 24) to 21.38, marking a decrease of 2.43.
• For Enterprise Value (Cr.), as of Mar 25, the value is 929.27. It has decreased from 1,342.13 (Mar 24) to 929.27, marking a decrease of 412.86.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has decreased from 1.78 (Mar 24) to 1.16, marking a decrease of 0.62.
• For EV / EBITDA (X), as of Mar 25, the value is 8.76. This value is within the healthy range. It has decreased from 13.43 (Mar 24) to 8.76, marking a decrease of 4.67.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 77.51 (Mar 24) to 0.00, marking a decrease of 77.51.
• For Price / BV (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has decreased from 2.10 (Mar 24) to 1.59, marking a decrease of 0.51.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness